Shares in small-cap biotech Orthocell (ASX: OCC) edged higher today (around 4% at the time of writing) after the company released a clinical update that could prove more important than the market initially realised.
At the centre of the announcement is Remplir, Orthocell’s nerve repair product, which continues to deliver strong clinical outcomes.
Strong treatment success rate
Orthocell reported an overall treatment success rate of 89.7% across 66 patients and 78 procedures, based on its ongoing real-world evidence study. That’s a strong headline number with solid supporting evidence.
In motor nerve repair procedures, more than 90% of procedures resulted in functional muscle recovery. Meanwhile, in nerve decompression procedures (which are typically used to treat chronic pain, numbness, and tingling) 89% of patients experienced significant improvement or complete relief.
Importantly, these results were achieved across a broad patient group, covering different types of nerve injuries and age ranges. That kind of consistency suggests the product’s effectiveness isn’t limited to narrow use cases.
Just as critical is the safety profile. The study reported no post-treatment complications or adverse effects, reinforcing confidence for surgeons considering adoption.
Why this matters
For investors the focus is on what this means commercially.
Orthocell is already seeing growing adoption, with more than 300 surgeons across over 220 hospitals in Australia using Remplir. Early traction is also building in the US, including procedures within a Department of Defense hospital network.
These are all emerging signs of real value being created which can hopefully translate into repeat usage, broader adoption, and ultimately, strong revenue growth.
Orthocell is now pushing into larger markets, with US expansion underway and Europe and the UK firmly in its sights. Regulatory approval in those regions is targeted for 2026, which could significantly expand its addressable market.
If the current clinical outcomes continue to hold and surgeon adoption keeps building, Orthocell may be moving closer to that key inflection point where a promising product becomes a scalable commercial business.
Foolish bottomline
Orthocell’s latest update strengthens the case that Remplir can be widely adopted. For investors, that’s a critical datapoint and if momentum continues, this could be the early stages of a much larger growth story.
The post This ASX biotech hit a 90% success rate. Can it unlock commercial growth? appeared first on The Motley Fool Australia.
Should you invest $1,000 in Orthocell right now?
Before you buy Orthocell shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Orthocell wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 20 Feb 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Are Orthocell shares a buy after crashing 7% yesterday?
- Orthocell caps 26% surge this week with first US Military Surgery
- Orthocell shares soar 22% on landmark US breakthrough
Motley Fool contributor Kevin Gandiya has no positions in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Orthocell. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.